Introduction:
Seqirus, a global leader in influenza prevention and influenza pandemic responseplans to construct a new next-generation vaccine manufacturing facility. The new manufacturing facility will be located in Australia.
Features:
The state-of-the-art facilitywill be constructed with an investment of US$800 million. This facility makes use of innovative cell-based technology for the production of influenza vaccinesfor both influenza pandemics and seasonal vaccination programs.
The manufacturing facility is being constructed to provide influenza vaccinesto Australia and rest of the world. The facility is supposed to be the only cell-based influenzavaccine productionfacility in the Southern Hemisphere. Moreover, it also produces a material known as Seqirus’ proprietary adjuvant MF59®. MF59®added to the vaccines will improve immune responsebydecreases the amount of antigen required for each vaccine and thus enabling for the production of doses more rapidly.
Cell-based influenza vaccine technology offers many advantages over the current process togetherwith more scalability and offering faster production.
The new state-of-the-art manufacturing facility is expected to be completed and be operational by mid-2026.
Specifications:
| Name | Seqirus |
| Type | New Construction |
| Budget | US$800 million |
| Year | 2026 |
